Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1983 1
1984 1
1987 1
1988 2
1989 3
1990 2
1991 6
1992 3
1993 7
1994 11
1995 4
1996 12
1997 9
1998 6
1999 4
2000 17
2001 18
2002 20
2003 24
2004 35
2005 43
2006 49
2007 35
2008 33
2009 71
2010 44
2011 53
2012 66
2013 73
2014 59
2015 52
2016 49
2017 53
2018 56
2019 68
2020 70
2021 62
2022 72
2023 57
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

1,137 results

Results by year

Filters applied: . Clear all
Page 1
N-cadherin upregulation mediates adaptive radioresistance in glioblastoma.
Osuka S, Zhu D, Zhang Z, Li C, Stackhouse CT, Sampetrean O, Olson JJ, Gillespie GY, Saya H, Willey CD, Van Meir EG. Osuka S, et al. J Clin Invest. 2021 Mar 15;131(6):e136098. doi: 10.1172/JCI136098. J Clin Invest. 2021. PMID: 33720050 Free PMC article.
Mechanistically, elevated N-cadherin expression resulted in the accumulation of beta-catenin at the cell surface, which suppressed Wnt/beta-catenin proliferative signaling, reduced neural differentiation, and protected against apoptosis through Clusterin secretion. N-cadhe …
Mechanistically, elevated N-cadherin expression resulted in the accumulation of beta-catenin at the cell surface, which suppressed Wnt/beta- …
BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling.
Shaashua L, Ben-Shmuel A, Pevsner-Fischer M, Friedman G, Levi-Galibov O, Nandakumar S, Barki D, Nevo R, Brown LE, Zhang W, Stein Y, Lior C, Kim HS, Bojmar L, Jarnagin WR, Lecomte N, Mayer S, Stok R, Bishara H, Hamodi R, Levy-Lahad E, Golan T, Porco JA Jr, Iacobuzio-Donahue CA, Schultz N, Tuveson DA, Lyden D, Kelsen D, Scherz-Shouval R. Shaashua L, et al. Nat Commun. 2022 Oct 31;13(1):6513. doi: 10.1038/s41467-022-34081-3. Nat Commun. 2022. PMID: 36316305 Free PMC article.
Tumors initiate by mutations in cancer cells, and progress through interactions of the cancer cells with non-malignant cells of the tumor microenvironment. ...In particular, we detect an increase in a subset of immune-regulatory clusterin-positive CAFs in BRC …
Tumors initiate by mutations in cancer cells, and progress through interactions of the cancer cells with non-malignant cells o …
Clusterin Expression in Colorectal Carcinomas.
Téllez T, Martin-García D, Redondo M, García-Aranda M. Téllez T, et al. Int J Mol Sci. 2023 Sep 27;24(19):14641. doi: 10.3390/ijms241914641. Int J Mol Sci. 2023. PMID: 37834086 Free PMC article. Review.
Colorectal cancer is the third most diagnosed cancer, behind only breast and lung cancer. ...The aim of this paper is to review the current genetic knowledge on the role of CLU in tumorigenesis and cancer progression in general, and discuss its possibl …
Colorectal cancer is the third most diagnosed cancer, behind only breast and lung cancer. ...The aim of this paper is t …
The role and function of CLU in cancer biology and therapy.
Zhang Y, Lv X, Chen L, Liu Y. Zhang Y, et al. Clin Exp Med. 2023 Sep;23(5):1375-1391. doi: 10.1007/s10238-022-00885-2. Epub 2022 Sep 13. Clin Exp Med. 2023. PMID: 36098834 Review.
Accumulated evidence has shown the prominent role of CLU in regulating several essential physiological processes, including programmed cell death, metastasis, invasion, proliferation and cell growth via regulating diverse signaling pathways to mediate cancer progression in …
Accumulated evidence has shown the prominent role of CLU in regulating several essential physiological processes, including programmed cell …
Clusterin (CLU) and prostate cancer.
Rizzi F, Bettuzzi S. Rizzi F, et al. Adv Cancer Res. 2009;105:1-19. doi: 10.1016/S0065-230X(09)05001-5. Adv Cancer Res. 2009. PMID: 19879420 Review.
The role of clusterin (CLU) in prostate tumorigenesis is probably the most highly controversial, with evidence that CLU expression is increased or decreased in different cancer models. ...In contrast with the hypothesis that CLU is a positive modulator of prostate …
The role of clusterin (CLU) in prostate tumorigenesis is probably the most highly controversial, with evidence that CLU expression is …
Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy.
Praharaj PP, Patra S, Panigrahi DP, Patra SK, Bhutia SK. Praharaj PP, et al. Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188500. doi: 10.1016/j.bbcan.2020.188500. Epub 2020 Dec 29. Biochim Biophys Acta Rev Cancer. 2021. PMID: 33385484 Review.
Clusterin (CLU) is an evolutionary conserved molecular chaperone present in different human tissues and fluids and established to be a significant cancer regulator. It controls several cancer-associated cellular events, including cancer cell proliferat …
Clusterin (CLU) is an evolutionary conserved molecular chaperone present in different human tissues and fluids and established to be …
Clusterin (CLU) and lung cancer.
Panico F, Rizzi F, Fabbri LM, Bettuzzi S, Luppi F. Panico F, et al. Adv Cancer Res. 2009;105:63-76. doi: 10.1016/S0065-230X(09)05004-0. Adv Cancer Res. 2009. PMID: 19879423 Review.
Lung cancer is the leading cause of cancer-related mortality. It is categorized into two histological groups that have distinct clinical behaviors, the nonsmall cell lung cancers (NSCLC) and the small cell lung cancer (SCLC). ...Studies performed in lu …
Lung cancer is the leading cause of cancer-related mortality. It is categorized into two histological groups that have distinc …
Posttranscription regulation of prostate cancer growth.
Shen L, Pili R. Shen L, et al. Cancer J. 2008 Jan-Feb;14(1):46-53. doi: 10.1097/PPO.0b013e318162108a. Cancer J. 2008. PMID: 18303483 Review.
A critical factor responsible for the malignant progression of prostate cancer is the abnormal expression and function of specific proteins. ...In this article we will review some of the key molecular targets and posttranscriptional strategies that are currently being test …
A critical factor responsible for the malignant progression of prostate cancer is the abnormal expression and function of specific pr …
Antisense approaches in prostate cancer.
Chi KN, Gleave ME. Chi KN, et al. Expert Opin Biol Ther. 2004 Jun;4(6):927-36. doi: 10.1517/14712598.4.6.927. Expert Opin Biol Ther. 2004. PMID: 15174974 Review.
Patients with hormone refractory prostate cancer have limited treatment options and new therapies are urgently needed. ...The current status and future direction of a number of antisense oligonucleotides targeting several genes, including BCL-2, BCL-XL, clusterin, t …
Patients with hormone refractory prostate cancer have limited treatment options and new therapies are urgently needed. ...The current …
The Ins and Outs of Clusterin: Its Role in Cancer, Eye Diseases and Wound Healing.
Gross C, Guérin LP, Socol BG, Germain L, Guérin SL. Gross C, et al. Int J Mol Sci. 2023 Aug 24;24(17):13182. doi: 10.3390/ijms241713182. Int J Mol Sci. 2023. PMID: 37685987 Free PMC article. Review.
Clusterin (CLU) is a glycoprotein originally discovered in 1983 in ram testis fluid. ...In this article, we review the actual knowledge about CLU at both the protein and gene expression level in wound healing, and explore the possibility that CLU is a key factor in canc …
Clusterin (CLU) is a glycoprotein originally discovered in 1983 in ram testis fluid. ...In this article, we review the actual knowled …
1,137 results